Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD.

To get sample report with TOC Click Here: http://www.researchmoz.com/enquiry.php?type=sample&repid=193674

To Browse a Full Report with TOC: http://www.researchmoz.us/mobile-operators-go-after-the-connected-car-opportunity-cellular-telematics-value-chain-business-models-and-market-forecast-report.html

The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lillys Cymbalta, and Otsuka/BMSs Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takedas Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Highlights

Key Questions Answered

- What will be the impact of imminent patent expiries for top selling products, such as Eli Lillys Cymbalta and Otsuka/BMSs Abilify in the MDD market?

- What do physicians think about Lundbeck/Takedas Brintellix and what will be the impact of its 2014 launch in the MDD market?

- What is the significance of late-phase pipeline products and how will their launch shape the future treatment landscape in MDD?

- What are the significant unmet needs in the MDD market?

- What are the remaining opportunities in the MDD market?

Key Findings

- Minimal growth in the MDD market is expected from 2013 to 2023. The key drivers will be the increasing uptake for Lundbeck/Takedas Brintellix, the potential introduction of seven late-stage pipeline drugs into the MDD market, and the increasing number of prevalent cases of MDD.

- Key players develop...